MMP12 is a Potential Predictive and Prognostic Biomarker of Various Cancers Including Lung Adenocarcinoma.

Autor:	Li GS; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Tang YX; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Zhang W; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Li JD; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Huang HQ; Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Liu J; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Fu ZW; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., He RQ; Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Kong JL; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Zhou HF; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China., Chen G; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P. R. China.
Jazyk:	angličtina
Zdroj:	Cancer control : journal of the Moffitt Cancer Center [Cancer Control] 2024 Jan-Dec; Vol. 31, pp. 10732748241235468.
DOI:	10.1177/10732748241235468
Abstrakt:	Objective: This study sought to explore the clinical value of matrix metalloproteinases 12 ( MMP12 ) in multiple cancers, including lung adenocarcinoma (LUAD). Methods: Using >10,000 samples, this retrospective study demonstrated the first pan-cancer analysis of MMP12 . The expression of MMP12 between cancer groups and their control groups was analyzed using Wilcoxon rank-sum tests. The clinical significance of MMP12 expression in multiple cancers was assessed using receiver operating characteristic curves, Kaplan-Meier curves, and univariate Cox analysis. A further LUAD-related analysis based on 4565 multi-center and in-house samples was performed to verify the findings regarding MMP12 in pan-cancer analysis partly. Results: MMP12 mRNA is highly expressed in 13 cancers compared to their controls, and the MMP12 protein level is elevated in some of these cancers (e.g., colon adenocarcinoma) ( P < .05). MMP12 expression makes it feasible to distinguish 21 cancer tissues from normal tissues (AUC = 0.86). A high MMP12 expression is a prognosis risk factor in eight cancers, such as adrenocortical carcinoma (hazard ratio >1, P < .05). The elevated MMP12 expression is also a prognosis protective factor in breast-invasive carcinoma and colon adenocarcinoma (hazard ratio <1, P < .05). Some pan-cancer findings regarding MMP12 are verified in LUAD-MMP12 expression is upregulated in LUAD at both the mRNA and protein levels ( P < .05), has the potential to distinguish LUAD with considerable accuracy (AUC = .91), and plays a risk prognosis factor for patients with the disease ( P < .05). Conclusions: MMP12 is highly expressed in most cancers and may serve as a novel biomarker for the prediction and prognosis of numerous cancers. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu